Immunovant is heading into its May 29 earnings event carrying a sharply split set of signals — an unusually bullish options print colliding with a stubborn double-digit short position and a month of executive selling.
The most striking development this week is in the options market. Call buying has surged relative to puts, pushing the put/call ratio to 0.05 — the lowest reading of the past year and nearly three standard deviations below the 20-day average of 0.16. That is an exceptionally lopsided call-dominated setup, suggesting investors are reaching aggressively for upside exposure ahead of the May 29 event. The backdrop makes it notable: the stock is down 8.2% on the week and 10.3% over the past month, closing Tuesday at $26.29. Buyers of calls are leaning into a falling knife.
Short interest frames the other side of the trade. Shorts have held their ground at roughly 25.5% of the free float, up from about 23.7% at mid-April. The 30-day increase of around 6.6% in short shares shows the bear camp is not deterred by those call buyers. Borrow costs remain negligible at just 0.40% annualised, and availability is loose — shares available to borrow run at over four times the current short interest, meaning there is no mechanical squeeze pressure and no friction for new entrants on the short side. The days-to-cover figure of roughly 10.5 (per the most recent FINRA settlement data) underscores how large the short position is relative to daily trading volumes. The ORTEX short score of 71.3 — high but edging down from 74.8 earlier in the week — sits near the top decile across the universe, confirming this is one of the more heavily shorted names in the sector.
The Street picture is mixed but tilts cautious. The mean price target of $40.29 implies substantial upside from current levels, yet Goldman Sachs, the most recent mover, only raised its target to $32 in mid-April while keeping a Neutral rating. That is a below-consensus call from a firm whose action is worth noting. Guggenheim and HC Wainwright carry Buy ratings with targets of $44 and $35 respectively, while Truist holds at $22 with a Hold. The bull case centres on IMVT-1402's 81% responder rate in previously unresponsive patients and indications of durable off-treatment TRAb reduction. Bears point to persistently elevated TRAb levels as evidence that disease modification is not yet proven and that relapse risk remains a real commercial obstacle. The forward EPS improvement score ranks in the 82nd percentile — analysts expect a meaningful trajectory shift — but current profitability metrics remain deeply negative, and the price-to-book multiple has compressed about 8% over the past month alongside the stock's slide.
The insider tape adds another layer of caution. The 90-day net value of sales is just over $10.4 million, with CEO Eric Venker accounting for the bulk — selling more than 335,000 shares at prices around $24–$25 in early April. CFO Tiago Girao sold roughly $763k worth on April 23. The CTO and COO also trimmed positions in the same window. None of these sales are individually dramatic in percentage-of-company terms, but the clustering of C-suite sells across a compressed period — all occurring near current price levels — adds weight to the caution signal already embedded in the short interest.
Peer performance reinforces the relative weakness. ROIV, Immunovant's highest-correlated peer at 51% correlation, is down 4% on the week. PRME has shed 18%, and SYRE is off 11%. The weakness is not uniquely Immunovant's — the biotech cohort has broadly pulled back — but IMVT is down more than most, and the heavy short base means any negative data at the May 29 event could amplify the move.
The last confirmed earnings event, in February, saw the stock jump 14.3% on the day and add another 7% over the following week — a pattern that would be painful for the current short base if repeated. What to watch into May 29 is whether the call-buying wave is building a genuine momentum bet on a positive readout, or whether it reflects hedging activity by existing short holders seeking to cap their downside.
See the live data behind this article on ORTEX.
Open IMVT on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
